Clinical studies of combined photodynamic therapy using 5-fluorouracil and methyl-aminolevulinate in patients at high risk for squamous cell carcinoma

2013 ◽  
Author(s):  
Edward V. Maytin ◽  
Sara Lohser ◽  
Alejandra Tellez ◽  
Lauren Wene ◽  
Rim Ishak ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Photodynamic Therapy ◽  
High Risk ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Clinical Studies ◽  
Methyl Aminolevulinate

scholarly journals 066 Role of TGF-β1 in the resistance of squamous cell carcinoma to photodynamic therapy

2021 ◽  
Vol 141 (5) ◽  
pp. S12
Author(s):  
M. Gallego Rentero ◽  
M. Gutiérrez-Pérez ◽  
M. Portillo-Esnaola ◽  
M. Mataix ◽  
L. Najera ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Photodynamic Therapy ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Tgf Β1

Thermally activated delayed fluorescent photosensitizer for photodynamic therapy of oral squamous cell carcinoma under low laser intensity

2021 ◽  
Author(s):  
Shiqi Hu ◽  
Bin Huang ◽  
Yumei Pu ◽  
Chengwan Xia ◽  
Qian Zhang ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Photodynamic Therapy ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Laser Intensity ◽  
Thermally Activated

In this report, a new Thermally activated delayed fluorescent(TADF) molecule [2-(4-triphenylvinyl-phenyl)-anthraquinone (TPE-AQ)] was synthesized. This nanomaterial has satisfactory photostability. In vitro, it was indicated that these TADF nanoparticles (NPs) were...

scholarly journals Outcomes of Post-Operative Treatment with Concurrent Chemoradiotherapy (CRT) in High-Risk Resected Oral Cavity Squamous Cell Carcinoma (OCSCC): A Multi-Institutional Collaboration

2021 ◽  
Vol 28 (4) ◽  
pp. 2409-2419
Author(s):  
Arslan Babar ◽  
Neil M. Woody ◽  
Ahmed I. Ghanem ◽  
Jillian Tsai ◽  
Neal E. Dunlap ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
High Risk ◽  
Oral Cavity ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Demographic Data ◽  
Disease Free Survival ◽  
Total Sample ◽  
High Dose ◽  
Pathologic Features

Adjuvant chemoradiation (CRT), with high-dose cisplatin remains standard treatment for oral cavity squamous cell carcinoma (OCSCC) with high-risk pathologic features. We evaluated outcomes associated with different cisplatin dosing and schedules, concurrent with radiation (RT), and the effect of cumulative dosing of cisplatin. An IRB-approved collaborative database of patients (pts) with primary OCSCC (Stage I–IVB AJCC 7th edition) treated with primary surgical resection between January 2005 and January 2015, with or without adjuvant therapy, was established from six academic institutions. Patients were categorized by cisplatin dose and schedule, and resultant groups compared for demographic data, pathologic features, and outcomes by statistical analysis to determine disease free survival (DFS) and freedom from metastatic disease (DM). From a total sample size of 1282 pts, 196 pts were identified with high-risk features who were treated with adjuvant CRT. Administration schedule of cisplatin was not significantly associated with DFS. On multivariate (MVA), DFS was significantly better in patients without perineural invasion (PNI) and in those receiving ≥200 mg/m2 cisplatin dose (p < 0.001 and 0.007). Median DFS, by cisplatin dose, was 10.5 (<200 mg/m2) vs. 20.8 months (≥200 mg/m2). Our analysis demonstrated cumulative cisplatin dose ≥200 mg/m2 was associated with improved DFS in high-risk resected OCSCC pts.

5-Aminolevulinic acid photodynamic therapy for early-stage lip squamous cell carcinoma

2021 ◽  
pp. 102321
Author(s):  
Peiru Wang ◽  
Guolong Zhang ◽  
Linglin Zhang ◽  
Zhongxia Zhou ◽  
Lei Shi ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Photodynamic Therapy ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Aminolevulinic Acid ◽  
Early Stage
Sign in / Sign up

Export Citation Format

Share Document